{
  "id": 703450,
  "title": "Anti-Müllerian hormone predicts benefit of chemo + endocrine therapy in under-55s with breast cancer",
  "url": "https://urgent.news/2026/08/12/anti-mullerian-hormone-predicts-benefit-of-chemo-endocrine-therapy-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-12T21:00:02.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-anti-mllerian-hormone-benefit-chemo.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Anti-Müllerian hormone (AMH) appears to predict the benefit of chemotherapy plus endocrine therapy (CET) versus ET alone in premenopausal women younger than 55 years with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with a recurrence score (RS) ≤25, according to a study published online July 24 in the Annals of Oncology.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}